Yanase Toshihiko, Oki Yutaka, Katabami Takuyuki, Otsuki Michio, Kageyama Kazunori, Tanaka Tomoaki, Kawate Hisaya, Tanabe Makito, Doi Masaru, Akehi Yuko, Ichijo Takamasa
Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan.
Department of Community and Family Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Endocr J. 2018 Apr 26;65(4):383-393. doi: 10.1507/endocrj.EJ17-0456. Epub 2018 Mar 23.
New diagnostic criteria and the treatment policy for adrenal subclinical Cushing's syndrome (SCS) are proposed on behalf of the Japan Endocrine Society. The Japanese version has been published, and the essential contents are presented in this English-language version. The current diagnostic criteria for SCS have elicited two main problems: (i) the relatively low reliability of a low range of serum cortisol essential for the diagnosis by an overnight 1-mg dexamethasone suppression test (DST); (ii) different cutoff values for serum cortisol after a 1-mg DST compared with those of other countries. Thus, new criteria are needed. In the new criteria, three hierarchical cortisol cutoff values, 5.0, 3.0 and 1.8 μg/dL, after a 1-mg DST are presented. Serum cortisol ≥5 μg/dL after a 1-mg DST alone is considered sufficient to judge autonomous cortisol secretion for the diagnosis of SCS, and the current criterion based on serum cortisol ≥3 μg/dL after a 1-mg DST can continue to be used. Clinical evidence suggests that serum cortisol ≥1.8-2.9 μg/dL after a 1-mg DST is not always normal, so cases who meet the cutoff value as well as a basal adrenocorticotropic hormone (ACTH) level <10 pg/mL (or poor ACTH response to corticotropin-releasing hormone (CRH)) and nocturnal serum cortisol ≥5 μg/dL are proposed to have SCS. We suggest surgery if cases show serum cortisol ≥5 μg/dL after a 1-mg DST (or are disheartened by treatment-resistant problems) or suspicious cases of adrenal cancer according to tumor imaging.
日本内分泌学会提出了肾上腺亚临床库欣综合征(SCS)的新诊断标准和治疗策略。日文版已发表,本文给出其英文版本的主要内容。目前SCS的诊断标准引发了两个主要问题:(i)过夜1毫克地塞米松抑制试验(DST)诊断所必需的低血清皮质醇范围的可靠性相对较低;(ii)1毫克DST后血清皮质醇的截断值与其他国家不同。因此,需要新的标准。在新标准中,给出了1毫克DST后三个分级的皮质醇截断值,分别为5.0、3.0和1.8μg/dL。仅1毫克DST后血清皮质醇≥5μg/dL就被认为足以判断自主性皮质醇分泌以诊断SCS,基于1毫克DST后血清皮质醇≥3μg/dL的现行标准也可继续使用。临床证据表明,1毫克DST后血清皮质醇≥1.8 - 2.9μg/dL并不总是正常的,因此对于符合截断值以及基础促肾上腺皮质激素(ACTH)水平<10 pg/mL(或对促肾上腺皮质激素释放激素(CRH)的ACTH反应不佳)且夜间血清皮质醇≥5μg/dL的病例,建议诊断为SCS。如果病例在1毫克DST后显示血清皮质醇≥5μg/dL(或因治疗抵抗问题而沮丧)或根据肿瘤影像学怀疑为肾上腺癌,我们建议进行手术。